- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
- Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces $180 Million Private Placement
More ▼
Key statistics
On Friday, Spyre Therapeutics Inc (SYRE:NSQ) closed at 33.67, -29.81% below its 52-week high of 47.97, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 34.09 |
---|---|
High | 35.79 |
Low | 33.09 |
Bid | 13.53 |
Offer | 37.79 |
Previous close | 34.61 |
Average volume | 322.99k |
---|---|
Shares outstanding | 50.78m |
Free float | 46.23m |
P/E (TTM) | -- |
Market cap | 1.73bn USD |
EPS (TTM) | -71.35 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼